Compare AbbVie Inc (ABBV) vs JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) Price & Performance

AbbVie (ABBV) trades at $249.94, up 0.82% with strong technical momentum and bullish moving averages. The company demonstrates solid fundamentals with $61.16B revenue in 2025 and consistent earnings beats, though net margins have compressed from 20.4% in 2022 to 6.9%. Recent positive Phase 2 data for ELAHERE in ovarian cancer and institutional accumulation signal confidence. Technical indicators show support at $248 and resistance at $251, with the stock trading near analyst consensus targets.

Outlook remains positive with 70.7% analyst buy ratings and $278.69 price target, representing 11.5% upside. Key opportunities include immunology growth from Skyrizi/Rinvoq and pipeline advancements. Risks include patent cliffs in the 2030s, debt levels at 50.4% of assets, and margin pressure from competitive and pricing headwinds. The dividend yield and earnings recovery in 2026 forecast support the bullish case.

JEPQ trades at $60.00, up 0.54% with a bullish technical signal from moving averages. The ETF's covered-call strategy generates monthly income, with recent dividends of $0.70, $0.64, and $0.56. News highlights focus on retirement income strategies and tax implications of distributions. Institutional interest remains strong, with Bank of America increasing its stake by 8.9% in Q1 2026.

Outlook remains positive for income-focused investors, though the RSI suggests potential overbought conditions. Key risks include tax treatment of distributions and market volatility affecting the options strategy. The fund's $39 billion AUM and active management support its popularity for yield generation in retirement portfolios.